Современные возможности применения иммунотерапии в лечении рака шейки матки

Рак шейки матки (РШМ) – 4‑й по распространенности рак среди женщин во всем мире. Каждый год более чем у 500 тыс. женщин диагностируется РШМ, и это заболевание становится причиной 300 тыс. смертей во всем мире. Инфицирование вирусом папилломы человека является причиной РШМ в большинстве случаев. Болезнь в значительной степени возможно предотвратить путем проведения профилактической вакцинации. Примерно 90 % случаев РШМ диагностируются в странах с низким и средним уровнем дохода, где отсутствуют организованные программы скрининга и вакцинации против вируса папилломы человека. Особую группу при этом заболевании составляют пациентки, у которых развивается рецидивирующий / метастатический РШМ. На сегодняшний день наиболее перспективным направлением лекарственного лечения при данной патологии являются препараты, действующие на контрольные точки иммунитета – рецептор PD-1 / лиганд PD-L1, которые используются опухолью для блокирования иммунной системы. В статье представлен клинический случай, демонстрирующий эффективность применения ингибитора PD-1 пембролизумаба для лечения рецидивирующего / метастатического РШМ.

1. Kaprin A.D., Starinskiy V.V., Shakhzadova O.A. Malignant tumors in Russia in 2019 (incidence and mortality). Moscow: P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 2020. Pp. 15, 16. (In Russ.).

2. Bray F., Ferlay J., Soerjomataram I. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2018;0:1–31. DOI: 10.3322/caac.21492.

3. Crosbie E.J., Einstein M.H., Franceschi S., Kitchener H.C. Human papillomavirus and cervical cancer. Lancet 2013;382:889–99. DOI: 10.1016/S0140-6736(13)60022-7.

4. Small W.Jr., Bacon M.A., Bajaj A. et al. Cervical cancer: a global health crisis. Cancer 2017;123:2404–12. DOI: 10.1002/cncr.30667.

5. UNAIDS. The gap report. Available at: http://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf. DOI: 10.1002/ijc.31610.

6. Olorunfemi G., Ndlovu N., Masukume G. et al. Temporal trends in the epidemiology of cervical cancer in South Africa (1994–2012). Int J Cancer 2018;143:2238–49. DOI: 10.1002/ijc.31610.

7. Ghebre R.G., Grover S., Xu M.J. et al. Cervical cancer control in HIV-infected women: past, present and future. Gynecol Oncol Rep 2017;21:101–08. DOI: 10.1016/j.gore.2017.07.009.

8. Mukhtarulina S.V., Kaprin A.D. The reasons for the development of dysfunctions of the lower urinary tract in patients with invasive cervical cancer after radical hysterectomy (literature review). Eksperimentalnaya i klinicheskaya urologiya = Experimental and Clinical Urology 2016;(3):137–41. (In Russ.).

9. Gao K., Ding L., Li L. Analysis of clinical efficacy of intensity-modulated radiation therapy and the prognosis factors in advanced cervical cancer. Zhonghua Fu Chan Ke Za Zhi 2014;49(1):30–5.

10. Monk B.J. Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27(28):4649–55. DOI: 10.1200/JCO.2009.21.8909.

11. Tewari K.S., Sill M.W., Long H.J. et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370(8):734–43. DOI: 10.1056/NEJMoa1309748.

12. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33(17):1974–82. DOI: 10.1200/JCO.2014.59.4358.

13. Ferlay J., Ervik M., Lam F. et al. Global Cancer Observatory: cancer today. Lyon: International Agency for Research on Cancer, 2018.

14. Serdar Aydın, Hande Nur Öncü, Dilek Sema. Diagnostic performance of immediate colposcopy among women with high-risk human papillomavirus (HPV) other than HPV 16/18 and normal cytology. J Obstet Gynaecol Res 2021;47(2):720–5. DOI: 10.1111/jog.14597.

15. Yang W., Song Y., Lu Y.L. et al. Increased expression of programmed death (PD) 1 and its ligand PD-L1 correlates with impaired cellmediated immunity in highrisk human papillomavirus-related cervical intraepithelial neoplasia. Immunol 2013;139(4):513–22. DOI: 10.1111/imm.12101.

16. Heeren A.M., Punt S., Bleeker M.C. et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol 2016;29:753–63. DOI: 10.1038/modpathol.2016.64.

17. Liu C., Lu J., Tian H. et al. Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. Mol Med Rep 2017;15:1063–70. DOI: 10.3892/ mmr.2017.6102.

18. Mezache L., Paniccia B., Nyinawabera A., Nuovo G.J. Enhanced expression of PD-L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol 2015;28:1594–602. DOI: 10.1038/modpathol.2015.108.

19. Meng Y., Liang H., Hu J. et al. PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. J Cancer 2018;9:2938–45. DOI: 10.7150/jca.22532.

20. Feng Y.C., Ji W.L., Yue N., et al. The relationship between the PD-1/ PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance. Cancer Manag Res 2018;10:105–13. DOI: 10.2147/ CMAR.S152232.

21. Enwere E.K., Kornaga E.N., Dean M. et al. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol 2017;30:577–86. DOI: 10.1038/modpathol.2016.221.

22. Kosmaczewska A., Bocko D., Ciszak L. et al. Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression. Pathol Oncol Res 2012;18:479e489. DOI: 10.1007/s12253-011-9471-y.

23. Chambers C.A., Kuhns M.S., Egen J.G., Allison J.P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Ann Rev Immunol 2001;19:565e594. DOI: 10.1146/annurev.immunol.19.1.565.

24. Anderson A.C. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2014;2:393e398. DOI: 10.1158/2326-6066.CIR-14-0039.

25. Yan J., Zhang Y., Zhang J.P. et al. Tim-3 expression defines regulatory T cells in human tumors. PLoS One 2013;8:e58006. DOI: 10.1371/journal.pone.0058006.

26. Cao Y., Zhou X., Huang X. et al. Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS One 2013;8:e53834. DOI: 10.1371/journal.pone.0053834.

27. Lee L., Matulonis U. Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy? Gynecol Oncol 2019;154:236–45. DOI: 10.1016/j.ygyno.2019.03.255.

28. Mole R.H. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953;26:234–41. DOI: 10.1259/0007-1285-26-305-234.

29. Abuodeh Y., Venkat P., Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer 2016;40:25–37. DOI: 10.1016/j.currproblcancer.2015.10.001.

30. Takaya M., Niibe Y., Tsunoda S. et al. Abscopal effect of radiation on toruliform para-aortic lymph node metastases of advanced uterine cervical carcinoma – a case report. Anticancer Res 2007;27:499–503.

31. Rodriguez-Ruiz M.E., Vanpouille-Box C., Melero I. et al. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol 2018; 39:644–55. DOI: 10.1016/j.it.2018.06.001.

32. McCall N.S., Dicker A.P., Lu B. Beyond concurrent chemoradiation: the emerging role of PD-1/PD-L1 inhibitors in stage III lung cancer. Clin Cancer Res 2018;24:1271–6. DOI: 10.1158/1078-0432.CCR-17-3269.

33. Naumann R.W., Hollebecque A., Meyer T. et al. Safety and efficacy of nivolumab && monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol 2019;37:2825–34. DOI: 10.1200/JCO.19.00739.

34. Howitt B.E., Sun H.H., Roemer M.G. et al. Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. JAMA Oncol 2016;2(4):518–22. DOI: 10.1001/jamaoncol.2015.6326.

35. Chung H.C., Schellens J.H., Delord J.P. et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study. J Clin Oncol 2018;36(Suppl):abstr.5522. DOI: 10.1200/JCO.18.01265.

36. Frenel J.S., le Tourneau C., O’Neil B. et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 2017;35(36):4035–41. DOI: 10.1200/JCO.2017.74.5471.